abstract |
The present invention relates to a platform for using a zebrafish to screen post-treatments for treating and / or preventing myopia and keratoconus diseases. The present invention is based on the fact that one of the numerous SLRPs, lumican, plays an important role in the regulation of gene or fibril formation affecting the eye size of zebrafish, in addition to playing an important role in clinical myopia. Thus, the present invention uses a zebrafish model constructed to further identify drugs that affect the expression of lumican and collagen fibril formation and the regulation of eye size. These drugs are potential post-treatments for treating myopia and keratoconus diseases. |